Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Stephanie Yohay, Soyoung Kim, Mingqian Lin et al. Nov 03, 2025 pp. 6360-6360 10.1182/blood-2025-6360

Abstract Introduction: The use of Lenalidomide (Len) with bortezomib and daratumumab (dara)-based triplet and quadruplet regimens have signi...

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

Michael Slade, Julie Fortier, Mark Fiala et al. Nov 03, 2025 pp. 5851-5851 10.1182/blood-2025-5851

Abstract Chimeric antigen receptor (CAR) T cell therapies against B-cell Maturation Antigen (BCMA) are a highly effective therapy in patient...

Single-cell atlas of circulating immunity identifies shared specific DLBCL signatures predicting response to R-CHOP and CD19 CAR-t therapies

Sicong Zhang, Xiangrui Meng, Jiayi Han et al. Nov 03, 2025 pp. 3556-3556 10.1182/blood-2025-3556

Abstract Background While the immunological heterogeneity of diffuse large B cell lymphoma (DLBCL) involves both the tum...

The role of RhoA in diffuse large B-cell lymphoma

Ariana Jacobs, Dominique Jahn, Rebecca Wurm-Kuczera et al. Nov 03, 2025 pp. 5308-5308 10.1182/blood-2025-5308

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma. DLBCL is divided into two major...

Racial, geographic, and gender disparities in ischemic heart disease mortality in patients with multiple myeloma: A nationwide analysis (1999–2023).

Muhammad Waseem Tahir, Zubia Tahir, Abigail Emerson et al. Nov 03, 2025 pp. 8114-8114 10.1182/blood-2025-8114

Abstract Background: Ischemic heart disease (IHD) is a leading causes of mortality in the United States. Patients with MM face elevated IHD...

Impact of innate immune memory on MDS progression by TET2-driven inflammation

Alyssa Jarabek, Xenia Davis, Mary Oliver et al. Nov 03, 2025 pp. 1400-1400 10.1182/blood-2025-1400

Abstract Myelodysplastic syndrome (MDS) is a clonal, age-related bone marrow failure disorder. Mutations in the epigenetic regulator, TET2,...

Mutational patterns and prognosis in younger versus older AML patients with myelodysplasia-related gene mutations undergoing allogeneic hematopoietic stem cell transplantation

Li-Ping Guo, Yuqian Sun, Meng Lv et al. Nov 03, 2025 pp. 6071-6071 10.1182/blood-2025-6071

Abstract Introduction The international consensus classification (ICC) has identified nine specific mutations, including ASXL1, BCOR, EZH2,...

Graft vs host disease outcomes in early tacrolimus withdrawal following allogeneic hematopoietic stem cell transplant

Chase Junge, Cameron Ninos, Aric Hall et al. Nov 03, 2025 pp. 4242-4242 10.1182/blood-2025-4242

Abstract Background: Post-transplant cyclophosphamide (PTCy), mycophenolate mofetil, and tacrolimus have become a standa...

Risk of returning to work and disability pension in multiple myeloma patients in central Norway

Håkon Skjalg Selland Johnstuen, Torstein Kleveland, Tobias S. Slørdahl Nov 03, 2025 pp. 7920-7920 10.1182/blood-2025-7920

Abstract Multiple myeloma greatly impacts work ability and capacity in affected patients, compared to both the general population and to oth...

Cytokine profiling identifies an IL‑8/IL1RAP‑Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms (MPN) associated with high symptom burden and poor outcomes

Idoroenyi Amanam, Lucy Ghoda, Salman Otoukesh et al. Nov 03, 2025 pp. 5593-5593 10.1182/blood-2025-5593

Abstract Background Chronic inflammation, characterized by elevated proinflammatory cytokines within the bone marrow (BM...

The need for re-induction based on D14-residual acute myeloid leukemia in patients achieving complete remission predicts higher relapse rate and inferior post-remission survival

Abiola Bolarinwa, Mohammad Yousuf, Aref Al-Kali et al. Nov 03, 2025 pp. 1605-1605 10.1182/blood-2025-1605

Abstract Background: The primary goal of induction therapy in acute myeloid leukemia (AML) is to induce complete remission with (CR) or with...

Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL).

Maria Elena Nizzoli, Antonella Anastasia, Carola Boccomini et al. Nov 03, 2025 pp. 1004-1004 10.1182/blood-2025-1004

Abstract Background. The FOLL12 study demonstrated that in High tumor burden patients with Follicular lymphoma (FL) treated with immunochemo...

The sinister course of hemophagocytic lymphohistiocytosis

Archa Rajesh, Pranvi Boyapati, Amit Rajkarnikar et al. Nov 03, 2025 pp. 6561-6561 10.1182/blood-2025-6561

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a rare and life threatening disease that causes systemic hyperinflammation, which can l...

Update AML: Updated disease monitoring and treatment to enhance outcomes for pediatric AML (NCT07059975)

Joanna Yi, Alexandra Stevens, Shannon Conneely et al. Nov 03, 2025 pp. 8248-8248 10.1182/blood-2025-8248

Abstract Background and significance: Outcomes for children with acute myeloid leukemia (AML) have not improved in decades, despite three co...

FGF11–HIF-1α glycolytic epigenetic axis drives AML progression and chemoresistance via metabolic reprogramming

Hang Lv, Jiayao He, Xin Zhuang et al. Nov 03, 2025 pp. 3185-3185 10.1182/blood-2025-3185

Abstract BackgroundAcute myeloid leukemia (AML) remains a lethal hematologic malignancy characterized by clonal expansion of immature myeloi...

Keeping it renal: Results of applying guideline-based management in sickle cell nephropathy

Elena Wernecke, Siera Gollan, Abdullah Kutlar Nov 03, 2025 pp. 1181-1181 10.1182/blood-2025-1181

Abstract Introduction Current guidelines for the treatment of sickle cell nephropathy (SCN) endorse initiating angiotensin-converting enzyme...

COVID-19 IgG antibodies drive endothelial cell activation and dysfunction

Bhagwati Joshi, Charles Sukin, Wolfram Ruf et al. Nov 03, 2025 pp. 3096-3096 10.1182/blood-2025-3096

Abstract The effect of COV-19 infection or post-acute sequelae of SARS-CoV-2 (PASC) increases risk of thrombotic events. The mechanism under...

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Abhishek Kataria, Mikhaila Rice, Wei Wei et al. Nov 03, 2025 pp. 2737-2737 10.1182/blood-2025-2737

Abstract Introduction: Patients (pts) with relapsed/refractory (RR) lymphoma frequently require urgent inpatient (inpt) admission for sympto...

Allogeneic hematopoietic cell transplantation risk stratification and eligibility using race-neutral versus race-specific pulmonary equations

Felipe Soto, Gordon Smilnak, Adarsh Suresh et al. Nov 03, 2025 pp. 4306-4306 10.1182/blood-2025-4306

Abstract Background: Pulmonary function tests, forced expiratory volume in 1 s (FEV₁) and diffusing capacity for carbon monoxide (DLCO), are...

A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation

Vaidehi Krishnan, Xi Ren, Kian Leong Lee et al. Nov 03, 2025 pp. 74-74 10.1182/blood-2025-74

Abstract Introduction Treatment-free remission (TFR) remains unpredictable in chronic myeloid leukemia (CML) management, with half of patien...

HLA and non-HLA factors in haploidentical donor selection: Insights from a brazilian single-center study

Newton Centurião, Leonardo Arcuri, Cinthya Da Silva et al. Nov 03, 2025 pp. 2435-2435 10.1182/blood-2025-2435

Abstract Introduction: Haploidentical bone marrow transplantation has emerged as the predominant form of allogeneic tran...

Development of the sickle cell outcome grading system (SCOGS), a novel classification system for sickle cell disease severity

Tarun Aurora, Renee Hodges, Joseph Wardell et al. Nov 03, 2025 pp. 2942-2942 10.1182/blood-2025-2942

Abstract Background Sickle cell disease (SCD) is a chronic, multisystem condition. This disorder causes red blood cells to sickle, resulting...

FK506 improves B cell reconstitution after allo-HSCT compared to csa: A real-world study

Hao Zhou, Guangyu Zhou, Wenqiong Xiang et al. Nov 03, 2025 pp. 6018-6018 10.1182/blood-2025-6018

Abstract Background Immune reconstitution is closely associated with various transplant-related complications following allogeneic hematopoi...

Iguratimod plus low-dose rituximab as second-line treatment in adults with primary immune thrombocytopenia: A multicenter, open-label, randomized, controlled, Phase 2 trial

Qiu-Sha Huang, Zhuo-Yu An, Peng Zhao et al. Nov 03, 2025 pp. 3044-3044 10.1182/blood-2025-3044

Abstract Introduction The optimal treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) remains uncertain. Igurat...

A flk-independent pathway of megakaryopoiesis is differentially responsive to stress and can produce high proportions of functionally distinct platelets

Kathleen McGrath, Michael Malloy, Taylor Carlson et al. Nov 03, 2025 pp. 4803-4803 10.1182/blood-2025-4803

Abstract Platelets and megakaryocytes (Mks) are increasingly recognized as diverse and dynamic cells that serve as critical components of th...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page